Pharmacogenetics and drug-induced arrhythmias

被引:83
作者
Roden, DM [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Clin Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0008-6363(00)00302-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drugs are widely recognized to vary in the beneficial and undesirable effects they produce in human subjects. The understanding that variants (polymorphisms and mutations) in the human genome are common and may well modulate both disease and its response to drugs, is a critical new concept in understanding mechanisms of drug action and their variability in human subjects. Variability can arise because of variability in genes encoding molecules of drug disposition, in genes encoding molecules that drugs target, or in genes that modulate the overall activity of the complex biological systems within which drugs act. The evolving understanding of the genetic basis of variability in response to drugs used in the treatment of sudden cardiac death has important implications not only for the treatment of patients who have survived an episode, but also for helping formulate a framework for further understanding mechanisms of drug action at the genetic level. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:224 / 231
页数:8
相关论文
共 53 条
[1]   MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia [J].
Abbott, GW ;
Sesti, F ;
Splawski, I ;
Buck, ME ;
Lehmann, WH ;
Timothy, KW ;
Keating, MT ;
Goldstein, SAN .
CELL, 1999, 97 (02) :175-187
[2]   Brugada syndrome - Clinical data and suggested pathophysiological mechanism [J].
Alings, M ;
Wilde, A .
CIRCULATION, 1999, 99 (05) :666-673
[3]   DELETION POLYMORPHISM IN THE GENE FOR ANGIOTENSIN-CONVERTING ENZYME IS A POTENT RISK FACTOR FOR MYOCARDIAL-INFARCTION [J].
CAMBIEN, F ;
POIRIER, O ;
LECERF, L ;
EVANS, A ;
CAMBOU, JP ;
ARVEILER, D ;
LUC, G ;
BARD, JM ;
BARA, L ;
RICARD, S ;
TIRET, L ;
AMOUYEL, P ;
ALHENCGELAS, F ;
SOUBRIER, F .
NATURE, 1992, 359 (6396) :641-644
[4]   PROARRHYTHMIC EFFECTS OF THE CLASS-III AGENT ALMOKALANT - IMPORTANCE OF INFUSION RATE, QT DISPERSION, AND EARLY AFTERDEPOLARIZATIONS [J].
CARLSSON, L ;
ABRAHAMSSON, C ;
ANDERSSON, B ;
DUKER, G ;
SCHILLERLINHARDT, G .
CARDIOVASCULAR RESEARCH, 1993, 27 (12) :2186-2193
[5]   Exaggerated QT prolongation after cardioversion of atrial fibrillation [J].
Choy, AMJ ;
Darbar, D ;
Dell'Orto, S ;
Roden, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (02) :396-401
[6]   TORSADES-DE-POINTES AS A MANIFESTATION OF MEXILETINE TOXICITY [J].
COCCO, G ;
STROZZI, C ;
CHU, D ;
PANSINI, R .
AMERICAN HEART JOURNAL, 1980, 100 (06) :878-880
[7]  
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[8]  
Dessertenne F, 1966, Arch Mal Coeur Vaiss, V59, P263
[9]   KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome [J].
Donger, C ;
Denjoy, I ;
Berthet, M ;
Neyroud, N ;
Cruaud, C ;
Bennaceur, M ;
Chivoret, G ;
Schwartz, K ;
Coumel, P ;
Guicheney, P .
CIRCULATION, 1997, 96 (09) :2778-2781
[10]  
Drolet B, 1999, J PHARMACOL EXP THER, V288, P1261